Dr Glen Clack Senior Medical Director Oncology Translational Medicine Unit AstraZeneca Challenges and Opportunities 2 Author 00 Month Year Set area descriptor Sub level 1 Barriers Perceived by Pharma ID: 186286
Download Presentation The PPT/PDF document "Developing Molecularly Targeted Therapie..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Developing Molecularly Targeted Therapies in Combination With Radiation:
Dr Glen ClackSenior Medical DirectorOncology Translational Medicine UnitAstraZeneca
Challenges and OpportunitiesSlide2
2
Author | 00 Month YearSet area descriptor | Sub level 1Slide3
Barriers Perceived by Pharma
Preclinical Testing and Model SystemsFunding Sources and Selection of Candidate Agents of Interest
Determining the Sequence of Combining RadiationPhase I Clinical Safety
Path to Registration
CommercialSlide4
Workshop for development of radiosensitisers, NCI, August 8–9, 2012: key recommendations
Prioritizing agent development
Biomarker-based
patient selection
available
(
If not concurrent
development of predictive biomarkers
during
the preclinical and early clinical phases of testing followed by subsequent clinical
validation)
Mandate pretreatment tumour biopsy and/or serum collection; ideally serially during early therapy and at the time of recurrence. Understanding proper sequencing of combining targeted agents with radiation therapySafety Phase I studies critical to determine the safety combinatio with radiation/chemoradiation; only a site-specific and not disease-specific requirement Minimal 30-day observational period after completion of radiotherapy should be used to gauge the acute toxicities of a novel treatmentClinical trial designs Innovative phase I designs (eg, time-to-event continuous reassessment method); improve study efficiency and cumulative safety analysis. Modular clinical trial platform, in which several agents/combinations are individually tested in parallel noncomparative armsRegulatory Better engagement with Regulators and pharma The FDA should issue an advisory clarifying requirements for approval of an agent in combination with radiotherapy The development of novel radiation sensitizers should be financially supported consistent with other priorities in cancer research
4Slide5
AZ Clinical Radiation combinations: DDR agents
5
Author | 00 Month Year
Set area descriptor | Sub level 1
Drug
Study
Combination partners
Disease
AZD (DNAPK)
Strong interest
Plus RT
NSCLC, SCLCAZD0156 (ATM)Strong interestPlus RTNot definedAZD6738 (ATR)PATRIOT/CRUKPlus RTDose escalation; then parallel tracks above/below diaphragmAZD1775 (WEE1)PN018Plus gemcitabine/RTPancreasPN013/CTEPPlus temozolamide/RTNewly diagnosed GBMPN016/CTEPPlus RTChildhood pontine GBMPN015/CTEPPlus cisplatin/RTCervixOlaparib (PARP)Study 25
Plus RT
Inoperable metastatic breast
Study 41
Plus RT +/- cisplatin
NSCLC
Study 61
Plus RT
Relapsed GBM
Study 31
Combo with C225 and RT
HNSCC
Study 42/COOLART
Plus RT
Laryngeal and
oropharyngeal
carcinoma
Study 28
Combo with
cis
,
pac
and
beva
Ovary newly diagnosed
Study 19
Plus RT
OesophagealSlide6
PATRIOT
Study DESIGN
Monotherapy
‘fast tracked’ dose escalation
Part A
‘All comers’
phase I population
Monotherapy
cohort expansion(s)
Part B
ATM-deficient
phase I populationRadiation combination dose escalation(2 parallel groups: tumours above or below diaphragm)Part CAll comersPalliative radiotherapy populationMonotherapy MTD, PoM, PK, PDcSafety, TolerabilityMonotherapy PoP, EfficacyPK, PDc, SafetyTolerabilityCombination therapy
PoP, Efficacy, PK, PDcSafety, Tolerability
Radiation combination cohort expansion
(2 parallel groups: tumours above or below diaphragm)
12-36 patients
12 (up to 36) patients
Up to 36 patients
12 patients
Monotherapy
‘end stage ‘disease and ‘maintenance’ opportunities
Radiation
potentiation
opportunities
Currently -
Dose escalation, part A
Cohort 3, 80 mg BD continuous dosing
Three sites recruiting –
RMH, Guy’s, UCHL
PI: Kevin HarringtonSlide7
7
Author | 00 Month YearSet area descriptor | Sub level 1
Confidentiality Notice
This file is
private and may contain confidential and proprietary information. If you have received this
file
in error, please
notify
us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this
file is
not permitted and may be unlawful
. AstraZeneca PLC, 2 Kingdom Street, London, W2 6BD, UK, T: +44(0)20 7604 8000, F: +44 (0)20 7604 8151, www.astrazeneca.comSlide8
8
Author | 00 Month YearSet area descriptor | Sub level 1Slide9
Barriers Perceived by Pharma
Preclinical Testing and Model SystemsLack of ability to translate pre-clinical work to clinicFunding Sources and Selection of Candidate Agents of Interest
Lack of portfolio driven strategy Lack of support from individual project teams
Determining the Sequence of Combining Radiation
Determining interactions between targeted agent, radiation and/or chemotherapy
Phase I Clinical Safety
Length of observational period
Path to Registration
End points
Lengthy development timelines
Commercial
Return on investmentSlide10
Output: 1st annual workshop for preclinical and clinical development of radiosensitisers, NCI, August 8–9, 2012
Summary of workshop recommendations for the accelerated development of novel targeted radiation enhancers
Determination of agent activity
1.1
Agents of interest should enhance radiation effects through either synergistic or additive mechanisms but, if not, should at least have single-agent or combination activity with chemotherapy.
1.2
Preclinical testing is crucial to provide evidence that the agent of interest has radiation enhancement effect; At least two cell lines from the same disease site should be required, whereas in vivo animal testing should be used to further demonstrate radiation enhancement effect whenever a suitable animal model for the cancer type exists.
1.3
When generation of in vitro or in vivo preclinical data is not feasible, strong justification must be provided for the inability to perform these studies before proposing a clinical study.
Prioritizing agent development
2.1
The development of radiation-enhancing agents should be prioritized when biomarker-based patient selection is available.2.2Agents without validated predictive biomarkers available for clinical testing could be brought into clinical testing but with the mandate that there are clear plans for concurrent preclinical research and clinical development of predictive biomarkers from pretreatment tissue specimens.2.3Concurrent development of predictive biomarkers should be a priority during the preclinical and early clinical phases of testing followed by subsequent clinical validation. Clinical studies must mandate pretreatment tumor biopsy and/or serum collection, with strong consideration given to acquisition of serial tissue collection during early therapy and at the time of recurrence.2.4Understanding the proper sequencing of combining targeted agents with radiation therapy will be important before carrying out large clinical trials.10Slide11
11
Summary of workshop recommendations for the accelerated development of novel targeted radiation enhancers
Safety
3.1
Phase I studies are critical to determine the safety of combining a new agent with radiation (or
chemoradiation
), but this should only be a site-specific and not a disease-specific requirement. For instance, clinical testing of a novel agent with radiation for rectal cancer need not be repeated for prostate cancer, cervical cancer, or other pelvic
tumors
.
3.2
A minimal 30-day observational period after completion of radiotherapy should be used to gauge the acute toxicities of a novel treatment.
3.3Late toxicity should be monitored in early-phase clinical trials even when acute toxicity is used as a primary safety endpoint.Clinical trial designs4.1Alternative innovative phase I designs (eg, time-to-event continuous reassessment method) should be considered to improve study efficiency and cumulative safety analysis.4.2An efficient way to rapidly test novel agents in combination with radiation is through a modular clinical trial platform, in which several agents/combinations are individually tested in parallel noncomparative arms.4.3The economic benefits and a platform-based clinical trial design should be recognized and prioritized.Regulatory5.1Both the US Food and Drug Administration (FDA) and the pharmaceutical industry should acknowledge that combination trials with radiation can help to dramatically improve cure rates of nonmetastatic patients, representing a new pathway for expediting the drug approval process. The FDA should issue an advisory clarifying requirements for approval of an agent in combination with radiotherapy or with a previously established chemotherapy and radiation therapy combination.5.2The Cancer Therapy Evaluation Program (CTEP) should consistently issue mass solicitations for drug combination trials that have specific calls for proposals in combination with radiation and simultaneously facilitate development of compounds as radiosensitizers within the CTEP portfolio.5.3The development of novel radiation sensitizers should be financially supported consistent with other priorities in cancer research.